|
Gender
|
Male
|
Male
|
Female
|
Female
|
|
Age (years)
|
49
|
56
|
28
|
22
|
|
SLE/APS
|
SLE
|
SLE
|
APS
|
APS
|
|
Years of SLE/APS
|
1.5
|
4
|
1
|
0.5
|
|
Steroids
|
yes
|
yes
|
no
|
no
|
|
Valve Lesion
|
MR
|
MR
|
MR
|
MR
|
|
NYHA class
|
IV
|
I
|
III
|
I
|
|
Echocardiography
| | | | |
|
-MR grade
|
4+
|
4+
|
4+
|
2+
|
|
-LV function
|
normal
|
normal
|
normal
|
normal
|
|
Cardiac Catheterization
| | | | |
|
-Coronary artery disease
|
no
|
no
|
no
|
NA
|
|
-PAP (mmHg) (N: 15-30/3-12 mmHg)
|
34/6
|
41/18
|
32/21
|
NA
|
|
-PCWP (mmHg) (N: 1-10 mmHg)
|
10
|
18
|
21
|
NA
|
|
-LVEDP (mmHg) (N: 3-12 mmHg)
|
10
|
18
|
19
|
NA
|
|
-Cardiac Output (L/min/m2) (N: 2.6-4.2 L/min/m2)
|
2.74
|
3.20
|
4.30
|
NA
|
|
Laboratory tests
| | | | |
|
-Repeated blood cultures
|
neg
|
neg
|
neg
|
neg
|
|
-CRP (mg/l) (N: 0-5 mg/l)
|
38
|
60
|
3
|
34
|
|
-White blood cell count (×109/l) (N: 4.0-10.0 × 109/l)
|
4.6
|
3.8
|
6.8
|
8.9
|
|
-Thrombocyte count (×109/l) (N: 150-300 × 109/l)
|
258
|
249
|
105
|
114
|
|
-Lupus anticoagulant (N: neg)
|
NA
|
NA
|
pos
|
pos
|
|
-Anti-cardiolipin Ab (IgG) (U/ml) (N: <10 U/ml)
|
<10
|
25
|
>100
|
53
|
|
-Anti-cardiolipin Ab (IgM) (U/ml) (N: <10 U/ml)
|
<10
|
<10
|
<10
|
<10
|
|
-Complement C3 (g/l) (N: 0.90-1.80 g/l)
|
0.39
|
0.77
|
1.19
|
1.57
|
|
-Complement C4 (g/l) (N: 0.10-0.40 g/l)
|
0.13
|
0.19
|
0.31
|
0.39
|
|
-Anti-Nuclear Antibody (ANA) titer (N: <20)
|
320
|
>640
|
40
|
40
|
|
-Anti-ds-DNA Ab (Farr-assay) (U/ml) (N: <10 U/ml)
|
11
|
154
|
<3
|
5
|
|
-Extractable Nuclear Antigens (ENA) (N: neg)
|
NA
|
neg
|
neg
|
neg
|
